Drug Profile
Peginterferon beta - Allozyne
Alternative Names: AZ 01; PEG-IFN-beta - AllozyneLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Allozyne
- Class Interferons; Proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 15 Apr 2016 No recent reports on development identified - Phase-I for Multiple sclerosis (In volunteers) in USA (Parenteral)
- 18 Oct 2011 Interim adverse events, pharmacokinetics and pharmacodynamics data from a phase Ib trial in volunteers released by Allozyne
- 11 Jan 2011 Topline adverse events and pharmacodynamics data from a phase I trial in Multiple sclerosis released by Allozyne